Browsing Tag
Janssen Biotech
7 posts
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Biocon Biologics secures license agreement for biosimilar launch in US
In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of…
Lupin Limited secures tentative FDA nod for generic Apalutamide Tablets
In a significant stride for global pharmaceuticals, Lupin Limited has garnered tentative approval from the United States Food…
EMA accepts MAA for Dong-A ST’s Stelara biosimilar, DMB-3115
Dong-A ST, the South Korean pharmaceutical company, has received confirmation from the European Medicine Agency (EMA) of the…
FDA grants emergency use authorization to Janssen COVID-19 vaccine
The US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) for the Janssen COVID-19…
Alligator Bioscience’s mitazalimab gets FDA approval for clinical trials in US
Swedish biotech company Alligator Bioscience has announced that the US Food and Drug Administration (FDA) has approved its…
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to…